Premium Class Action ESSA Pharma Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky LLP Before March 25, 2025 to Discuss Your Rights – EPIX ESSA Pharma’s Cash Management: A Potential Risk to Shareholder Value and Market Stability ESSA Pharma Inc. Reports Strategic Shift Amid Losses Premium The Fly Essa Pharma downgraded to Neutral from Overweight at Piper Sandler Essa Pharma downgraded to Perform from Outperform at Oppenheimer Essa Pharma downgraded to Hold from Buy at Jefferies Premium The Fly Essa Pharma reports Q3 EPS (16c), consensus (25c) ESSA Pharma’s Promising Prostate Cancer Trial Updates Essa Pharma reports Q2 EPS (20c), consensus (19c) Show More
You need to enable JavaScript to run this app. 
